Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX)

Delayed Data
As of Apr 24
 -0.98 / -20.99%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company, which focuses on the development and commercialization of prescription drugs targeting addiction and diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. The company has two products in development, and is currently evaluating its lead product GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin) for the treatment of cocaine addiction and it also expects to evaluate CPP-109 for the treatment of other addictions. It also develops CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects from those associated with vigabatrin. Catalyst Pharmaceutical Partners was founded by McEnany J. Patrick and Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.

Contact Information

Catalyst Pharmaceutical Partners, Inc.
355 Alhambra Circle
Coral Gables Florida 33134
P:(305) 529-2522
Investor Relations:



Other institutional26.32%
Individual stakeholders17.40%
Mutual fund holders10.20%

Top Executives

Patrick J. McEnanyChairman, President & Chief Executive Officer
Steven R. MillerChief Operating & Scientific Officer
Alicia GrandeChief Financial Officer, Treasurer & VP
Charles W. GorodetzkyChief Medical Officer
David D. MuthChief Commercial Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account